This study was aimed to evaluate the clinical effect and safety of Professor Huang Chunlin"s prescription for regulating spleen and relieving turbid to improve gastrointestinal function in peritoneal dialysis (PD) patients. Randomized controlled trial (RCT) was conducted among 59 cases of children with PD patients from PD clinic of Guangdong Provincial Hospital of Chinese Medicine, from December 2017 to December 2018. The patients were randomly divided into observation group (n=29) and control group (n=30). The observation group was given Chinese medicine combined with basic treatment, and the control group was treated by Bifidobacterium and basic treatment. Evaluation was given on the total clinical efficacy, gastrointestinal symptom rating scale (GSRS), TCM syndrome score and medication safety. Adverse reactions should be truthfully recorded. The GSRS score and TCM syndrome score of observation group were significantly decreased, which alleviated abdominal distension, improved appetite and softened stools, and no adverse reactions were observed. Compared with Bifidobacterium, Professor Huang Chunlin"s prescription can significantly improve gastrointestinal symptoms in PD patients.